pharma news today glp-1 obesity drug Agonists Weight Loss Drugs Market Report, 2025-2030 Market Overview: GLP-1 Agonists and

DHS can be localized, presenting as erythematous, pruritic wheals and plaques at injection sites, or generalized

compounding facilities that prepare medications according to the prescriptions they receive

J Am Soc Nephrology: JASN

Captive | Captive Insurance | Insurance Commissioner | Date Posted: Thursday, September 4, 2025 Prices for the medications were relatively flat, after subtracting rebates, the analysis of data provided to the OVBHCD by Delawares three largest pharmacy benefit managers found

While the term specifically references Ozempic, it can happen with any form of accelerated weight loss, whether from medication, surgery, or extreme dieting

(2023) Anti-obesity medication use for adolescent metabolic and bariatric surgery patients: a systematic literature review